Compare GDYN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDYN | VALN |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.3M | 536.9M |
| IPO Year | 2018 | 2021 |
| Metric | GDYN | VALN |
|---|---|---|
| Price | $5.68 | $5.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $10.67 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.9M | 26.0K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $111,283,000.00 | N/A |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $10.84 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.13 | $5.06 |
| 52 Week High | $12.86 | $12.25 |
| Indicator | GDYN | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 40.34 |
| Support Level | $5.27 | $5.11 |
| Resistance Level | $6.11 | $6.69 |
| Average True Range (ATR) | 0.48 | 0.19 |
| MACD | -0.14 | -0.01 |
| Stochastic Oscillator | 2.47 | 25.53 |
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.